Article Details

Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo ... - PR Newswire

Retrieved on: 2022-12-01 18:09:26

Tags for this article:

Click the tags to see associated articles and topics

Regeneron ESMO IO Presentations Highlight Potential of Fianlimab and Libtayo ... - PR Newswire. View article details on hiswai:

Excerpt

Phase 1 study of fianlimab: A human lymphocyte activation gene-3 (LAG-3) monoclonal antibody, in combination with cemiplimab in advanced NSCLC.

Article found on: www.prnewswire.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up